Patents by Inventor Revital RATTENBACH

Revital RATTENBACH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS COMPRISING GLP-1R AGONISTS
    Publication number: 20240293514
    Abstract: The present invention relates to a pharmaceutical composition comprising a GLP-1R agonist such as liraglutide or semaglutide, a buffer selected from a tromethamine buffer and a phosphate buffer, and an isotonic agent selected from glucose, a polyethylene glycol and glycerol. The present invention also relates to said pharmaceutical composition for use in a method for treating joint diseases.
    Type: Application
    Filed: June 23, 2022
    Publication date: September 5, 2024
    Inventors: Revital RATTENBACH, Francis BERENBAUM, Keren BISMUTH, Céline MARTIN, Coralie MEUROT
  • USE OF A COMPOUND SUCH AS PLERIXAFOR FOR TREATING A VIRAL PULMONARY DISEASE
    Publication number: 20240238244
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt and/or hydrate thereof, for use in the treatment of a viral pulmonary disease or a chronic respiratory distress syndrome (CRDS) resulting from a viral pulmonary disease in a subject, the disease being different from COVID-19, wherein formula (I) is Z—R-A-R?—Y, including plerixafor.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 18, 2024
    Applicants: 4LIVING BIOTECH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITE DE LILLE, CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
    Inventors: Revital RATTENBACH, Keren BISMUTH, Jérome BRETON, François TROTTEIN, Valentin SENCIO
  • NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE
    Publication number: 20230157994
    Abstract: A method of treating COVID-19 in a patient. The patient may be in moderate to advanced stages of COVID-19 infection. The method includes administering to the patient a therapeutically effective amount of at least one antagonist or inhibitor of chemokine receptor CXCR4. The at least one antagonist or inhibitor of chemokine receptor CXCR4 is distinct from hydroxychloroquine.
    Type: Application
    Filed: May 5, 2021
    Publication date: May 25, 2023
    Applicants: 4LIVING BIOTECH, UNIVERSITE DE BORDEAUX, CENTRE HOSPITALIER DE BORDEAUX, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM, INSTITUT PASTEUR DE LILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE LILLE
    Inventors: Patrick BERGER, Isabelle DUPIN, Renaud PREVEL, Chloé JAMES, Pierre-Olivier GIRODET, Keren BISMUTH, Revital RATTENBACH, Jérôme BRETON, Francois TROTTEIN, Valentin SENCIO
  • COMPOSITION AND METHODS FOR REGULATING CHONDROCYTE PROLIFERATION AND INCREASING OF CARTILAGE MATRIX PRODUCTION
    Publication number: 20210401944
    Abstract: A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and/or stem cell differentiation into chondrocytes.
    Type: Application
    Filed: November 18, 2019
    Publication date: December 30, 2021
    Applicants: 4MOVING BIOTECH, SORBONNE UNIVERSITE
    Inventors: Francis BERENBAUM, Revital RATTENBACH